These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 9215296)

  • 1. Differential gene expression of steroid 5 alpha-reductase 2 in core needle biopsies from malignant and benign prostatic tissue.
    Bjelfman C; Söderström TG; Brekkan E; Norlén BJ; Egevad L; Unge T; Andersson S; Rane A
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2210-4. PubMed ID: 9215296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steroid 5-alpha reductase type 2 activity in biopsies from malignant and normal prostatic tissues.
    Oliveira OL; Koff WJ; Muraro F; Santos EB; Gomes Soares DF; Trindade VM
    Clin Chim Acta; 2008 May; 391(1-2):36-40. PubMed ID: 18328817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Messenger ribonucleic acid levels of steroid 5 alpha-reductase 2 in human prostate predict the enzyme activity.
    Söderström TG; Bjelfman C; Brekkan E; Ask B; Egevad L; Norlén BJ; Rane A
    J Clin Endocrinol Metab; 2001 Feb; 86(2):855-8. PubMed ID: 11158057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content.
    Forti G; Salerno R; Moneti G; Zoppi S; Fiorelli G; Marinoni T; Natali A; Costantini A; Serio M; Martini L
    J Clin Endocrinol Metab; 1989 Feb; 68(2):461-8. PubMed ID: 2465302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
    Zhao Z; Liu J; Li S; Shen W
    Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age and Obesity Promote Methylation and Suppression of 5α-Reductase 2: Implications for Personalized Therapy of Benign Prostatic Hyperplasia.
    Bechis SK; Otsetov AG; Ge R; Wang Z; Vangel MG; Wu CL; Tabatabaei S; Olumi AF
    J Urol; 2015 Oct; 194(4):1031-7. PubMed ID: 25916673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mRNA expression analysis of human kallikrein 11 (KLK11) may be useful in the discrimination of benign prostatic hyperplasia from prostate cancer after needle prostate biopsy.
    Scorilas A; Gregorakis AK
    Biol Chem; 2006 Jun; 387(6):789-93. PubMed ID: 16800741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
    Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
    J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between 5-α reductase type 2 protein expression and methylation of 5-α reductase type 2 promotor gene of benign prostatic hyperplasia.
    Kang PM; Kim YJ; Seo WT; Kang SH; Kim TS; Chun BK; Seo WI; Jeong JY; Chung JI
    World J Urol; 2019 Apr; 37(4):709-718. PubMed ID: 30069579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of neural 5 alpha-reductase messenger ribonucleic acid: comparison to 5 alpha-reductase activity during prenatal development in the rat.
    Lephart ED; Andersson S; Simpson ER
    Endocrinology; 1990 Sep; 127(3):1121-8. PubMed ID: 2387251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate.
    Zhigang Z; Wenlu S
    Prostate; 2008 Feb; 68(2):190-9. PubMed ID: 18076024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of human androgens and prostatic diseases.
    Novelli G; Margiotti K; Sangiuolo F; Reichardt JK
    Pharmacogenomics; 2001 Feb; 2(1):65-72. PubMed ID: 11258198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of MENT on primary cell cultures from benign prostatic hyperplasia and prostate carcinoma.
    Mendoza P; Sánchez C; Contreras HR; Vergara J; Acevedo C; Cabezas J; Huidobro C; Noé G; Castellón EA
    Int J Androl; 2009 Dec; 32(6):607-15. PubMed ID: 18637152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate diseases--role of sex steroids and their inhibitors.
    Welén K; Damber JE
    Best Pract Res Clin Endocrinol Metab; 2011 Apr; 25(2):355-67. PubMed ID: 21397203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered androgen metabolism in metastatic prostate cancer.
    Kliman B; Prout GR; Maclaughlin RA; Daly JJ; Griffin PP
    J Urol; 1978 May; 119(5):623-6. PubMed ID: 77915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and regulation of steroid 5 alpha-reductase 2 in prostate disease.
    Silver RI; Wiley EL; Davis DL; Thigpen AE; Russell DW; McConnell JD
    J Urol; 1994 Aug; 152(2 Pt 1):433-7. PubMed ID: 7516976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen action: molecular mechanism and medical application.
    Liao S
    J Formos Med Assoc; 1994 Sep; 93(9):741-51. PubMed ID: 7735002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stable expression of constitutively-activated STAT3 in benign prostatic epithelial cells changes their phenotype to that resembling malignant cells.
    Huang HF; Murphy TF; Shu P; Barton AB; Barton BE
    Mol Cancer; 2005 Jan; 4(1):2. PubMed ID: 15647107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens.
    Monti S; Di Silverio F; Iraci R; Martini C; Lanzara S; Falasca P; Poggi M; Stigliano A; Sciarra F; Toscano V
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1700-6. PubMed ID: 11297606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5 alpha-reductase expression by prostate cancer cell lines and benign prostatic hyperplasia in vitro.
    Smith CM; Ballard SA; Worman N; Buettner R; Masters JR
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1361-6. PubMed ID: 8636334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.